Sera Prognostics (NASDAQ:SERA) Releases Earnings Results, Misses Expectations By $0.02 EPS

Sera Prognostics (NASDAQ:SERA) announced its quarterly earnings data on Wednesday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Zacks reports.

Sera Prognostics Stock Performance

NASDAQ SERA traded up $0.06 on Wednesday, reaching $4.14. The company’s stock had a trading volume of 57,077 shares, compared to its average volume of 142,782. The firm’s 50 day moving average is $5.15 and its two-hundred day moving average is $6.62. The stock has a market cap of $139.82 million, a PE ratio of -4.18 and a beta of 0.89. Sera Prognostics has a twelve month low of $3.84 and a twelve month high of $12.36.

Insider Buying and Selling

In other Sera Prognostics news, Director Joshua Phillips sold 12,710 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $7.40, for a total value of $94,054.00. Following the transaction, the director now owns 5 shares of the company’s stock, valued at approximately $37. This represents a 99.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert Gardner Harrison sold 14,209 shares of the stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now owns 116,837 shares of the company’s stock, valued at $863,425.43. This trade represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,877 shares of company stock worth $480,677 in the last ninety days. 15.80% of the stock is currently owned by corporate insiders.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.